Krystal Biotech, Inc.
KRYS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711279
In the last 90 days, Krystal Biotech, Inc. insiders filed 0 open-market purchases and 3 sales; 422 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Krystal Biotech, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +2 vs. Q2 2021
- Shares held
- 16.3M
- +511.4K (+3.2%) vs. Q2 2021
- Total value
- $850.7M
- −$222.4M (−20.7%) vs. Q2 2021
- New holders
- 12
- 45 more added
- Sold out
- 10
- 33 more reduced
2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KRYS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 422 | $11.1B |
| Q1 2026 | 368 | $7.32B |
| Q4 2025 | 334 | $7.01B |
| Q3 2025 | 284 | $4.94B |
| Q2 2025 | 275 | $3.80B |
| Q1 2025 | 299 | $4.98B |
| Q4 2024 | 264 | $4.35B |
| Q3 2024 | 283 | $5.15B |
| Q2 2024 | 245 | $5.24B |
| Q1 2024 | 234 | $4.49B |
| Q4 2023 | 194 | $3.03B |
| Q3 2023 | 188 | $2.76B |
| Q2 2023 | 183 | $2.71B |
| Q1 2023 | 160 | $1.68B |
| Q4 2022 | 154 | $1.66B |
| Q3 2022 | 148 | $1.45B |
| Q2 2022 | 137 | $1.36B |
| Q1 2022 | 135 | $1.37B |
| Q4 2021 | 140 | $1.35B |
| Q3 2021 | 113 | $850.7M |
| Q2 2021 | 113 | $1.12B |
| Q1 2021 | 113 | $1.27B |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Krystal Biotech, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 500,000 | $26.1M | 0.64% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 534,700 | $27.9M | 0.13% | +193,800+56.8% | Added |
| Baker Bros. Advisors LP | 607,735 | $31.7M | 0.14% | 00.0% | Unchanged |
| First Light Asset Management, LLC | 633,481 | $33.1M | 2.18% | +106,831+20.3% | Added |
| Pictet Asset Management SA | 637,492 | $33.3M | 0.04% | +637,492 | New |
| State Street Corp | 737,053 | $38.5M | 0.00% | +24,056+3.4% | Added |
| Frazier Management LLC | 771,250 | $40.3M | 3.22% | −16,626−2.1% | Reduced |
| Credit Suisse AG | 771,954 | $40.3M | 0.03% | +5,629+0.7% | Added |
| Vanguard Group Inc | 888,658 | $46.4M | 0.00% | +42,303+5.0% | Added |
| Lord, Abbett & Co. LLC | 1,067,158 | $55.7M | 0.13% | −124,422−10.4% | Reduced |
| BlackRock Inc. | 1,541,386 | $80.5M | 0.00% | +9,040+0.6% | Added |
| FMR LLC | 1,902,405 | $99.3M | 0.01% | +134,488+7.6% | Added |
| Redmile Group, LLC | 1,982,432 | $103.5M | 1.81% | −89,700−4.3% | Reduced |
| FIL Ltd | 0 | $0 | 0.00% | −176,799−100.0% | Sold out |
| Farallon Capital Management, L.L.C. | 0 | $0 | 0.00% | −75,000−100.0% | Sold out |
| DSAM Partners (London) Ltd | 0 | $0 | 0.00% | −70,274−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −7,859−100.0% | Sold out |
| Legato Capital Management LLC | 0 | $0 | 0.00% | −5,882−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −5,604−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −318−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −232−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −38−100.0% | Sold out |
| Whittier Trust Co | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| Pictet Asset Management Ltd | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |